Strain Name |
C57BL/6-Cd274tm1(CD274)Bcgen Sirpatm1(SIRPA)Bcgen Cd47tm1(CD47)Bcgen/Bcgen
|
Common Name | B-hPD-L1/hSIRPA/hCD47 mice |
Background | C57BL/6 | Catalog number |
130561 |
Aliases |
Cd274 (CD274 molecule,Also known as PD-L1); CD47 (CD47 molecule) ; SIRPα (Signal regulatory protein alpha) |
||
NCBI Gene ID |
16423,19261,60533 |
Strain specific PD-L1, CD47 and SIRPα expression analysis in homozygous B-hPD-L1/hSIRPA/hCD47 mice by flow cytometry. Splenocytes from both wild type (+/+) C57BL/6 and homozygous B-hPD-L1/hSIRPA/hCD47 (H/H) mice were analyzed by flow cytometry. Mouse PD-L1+ and CD47+ T cells were only detectable in the WT C57BL/6 mice. Human PD-L1+ and CD47+ T cells were only detectable in the homozygous B-hPD-L1/SIRPA/hCD47 mice. Mouse SIRPα was detectable in WT mice. This anti-mouse SIRPα antibody also reacts crossly with hSIRPα. Human SIRPα were exclusively detectable in homozygous B-hPD-L1/hSIRPa/hCD47 mice but not in WT mice.
Analysis of spleen T cell subpopulations in B-hPD-L1/hSIRPA/hCD47 mice
Antitumor activity of anti-human CD47/PD-L1 bispecific antibodies in B-hPD-L1/hSIRPA/hCD47 mice. (A) Anti-human CD47/PD-L1 bispecific antibody inhibited MC38-hPD-L1-hCD47 tumor growth in B-hPD-L1/hSIRPA/hCD47 mice (female, 6-8 week-old, n=5). Mice were grouped when tumor volume reached approximately 200 mm3, at which time they were treated with different antibodies with doses and schedules indicated in panel. (B) Body weight changes during treatment. As shown in panel A, the bispecific antibody showed better efficacy among these antibodies, demonstrating that the B-hPD-L1/hSIRPA/hCD47 mice provide a powerful preclinical model for in vivo evaluation of anti-human CD47/PD-L1 bispecific antibodies. Values are expressed as mean ± SEM.